

Niki Karachaliou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534077/publications.pdf>

Version: 2024-02-01

139
papers

6,301
citations

87401

40
h-index

87275

74
g-index

141
all docs

141
docs citations

141
times ranked

11538
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31
2	BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100113.	0.6	4
3	Mechanisms of resistance to osimertinib. <i>Journal of Thoracic Disease</i> , 2020, 12, 2851-2858.	0.6	62
4	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	0.5	17
5	Novel molecular targets for the treatment of lung cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 37-43.	1.1	20
6	Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 945-947.	1.3	1
7	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1810-1821.	1.3	7
8	SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. <i>IScience</i> , 2020, 23, 101832.	1.9	11
9	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093855.	1.0	8
10	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100084.	0.6	2
11	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1019-1028.	1.0	8
12	Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4567-4575.	1.0	14
13	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019, 13, 2633-2645.	2.1	69
14	Targeting PKC δ -PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. <i>Cell Communication and Signaling</i> , 2019, 17, 137.	2.7	21
15	BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. <i>Cancers</i> , 2019, 11, 1381.	1.7	44
16	Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. <i>Translational Lung Cancer Research</i> , 2019, 8, 340-351.	1.3	12
17	Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). <i>Thoracic Cancer</i> , 2019, 10, 508-518.	0.8	8
18	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78

#	ARTICLE	IF	CITATIONS
19	Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP). <i>Frontiers in Oncology</i> , 2019, 9, 254.	1.3	21
20	Co-mutations in EGFR driven non-small cell lung cancer. <i>EBioMedicine</i> , 2019, 42, 18-19.	2.7	16
21	Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy. <i>EBioMedicine</i> , 2019, 42, 20-21.	2.7	1
22	Cancer Stem Cell Biomarkers in EGFR-Mutation ⁺ Positive Non ⁺ Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 167-177.	1.1	37
23	Targeting PKC ^δ -PAK1 in EGFR-mutation positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 667-673.	1.3	11
24	Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). <i>International Journal of Biological Sciences</i> , 2019, 15, 2607-2614.	2.6	19
25	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non ⁺ Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 304-310.	0.5	10
26	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). <i>EBioMedicine</i> , 2019, 39, 207-214.	2.7	38
27	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. <i>Cancer Research</i> , 2019, 79, 546-556.	0.4	59
28	Adjuvant therapy for resected EGFR -mutant non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2018, 19, e126.	5.1	3
29	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	0.6	17
30	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876209.	1.4	102
31	RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 474-479.	1.2	16
32	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876462.	1.4	101
33	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876372.	1.4	3
34	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	1.4	30
35	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , 2018, 29, 112-127.	2.7	63
36	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200

#	ARTICLE	IF	CITATIONS
37	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501.	1.4	101
38	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	1.3	8
39	ARID1A Gene Driver Mutations in Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, e255-e257.	0.5	24
40	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879310.	1.4	14
41	Avelumab in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2018, 19, 1423-1424.	5.1	5
42	Rhombooids and regulation of receptor tyrosine kinase ligands shedding. <i>EBioMedicine</i> , 2018, 37, 19-20.	2.7	2
43	Anti-“Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1324-1337.	0.5	29
44	Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer. <i>EBioMedicine</i> , 2018, 33, 16-17.	2.7	4
45	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	1.1	21
46	Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma. <i>Lancet Respiratory Medicine</i> ,the, 2018, 6, 649-651.	5.2	1
47	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. <i>Current Oncology Reports</i> , 2018, 20, 70.	1.8	58
48	Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1117-1120.	1.0	4
49	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> ,the, 2018, 6, 771-781.	5.2	167
50	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 35-45.	1.5	42
51	Beyond platinum treatment for NSCLC: what does the future hold?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 293-295.	1.1	12
52	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 295-304.	0.9	12
53	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-“Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	1.5	62
54	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 802-810.	2.9	124

#	ARTICLE	IF	CITATIONS
55	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
56	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722.	1.9	17
57	Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). <i>Targeted Oncology</i> , 2017, 12, 513-523.	1.7	21
58	P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1074-S1075.	0.5	1
59	P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1216-S1217.	0.5	0
60	OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S281-S282.	0.5	1
61	MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. <i>Journal of Thoracic Oncology</i> , 2017, 12, S379-S380.	0.5	15
62	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S435-S436.	0.5	1
63	Using genetics to predict patient response to platinum-based chemotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 21-32.	0.4	7
64	HER3 as a Therapeutic Target in Cancer. <i>BioDrugs</i> , 2017, 31, 63-73.	2.2	29
65	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017, 60, 1-11.	3.4	29
66	BRAFV600E and BRAF-inactivating mutations in NSCLC. <i>Lancet Oncology</i> , The, 2017, 18, 1286-1287.	5.1	6
67	Brain metastases in patients with EGFR -mutant non-small-cell lung cancer. <i>Lancet Respiratory Medicine</i> , 2017, 5, 669-671.	5.2	4
68	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , 2017, 32, 238-252.e9.	7.7	235
69	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	2.0	26
70	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125.	1.3	49
71	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 47305-47316.	0.8	40
72	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	0.8	277

#	ARTICLE	IF	CITATIONS
73	Innate resistance in EGFR mutant non-small-cell lung cancer patients by co-activation of receptor tyrosine kinases(RTKs). <i>Annals of Oncology</i> , 2017, 28, ix13.	0.6	0
74	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, S1364-S1372.	0.6	13
75	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 1066-1075.	0.8	172
76	Human endogenous retroviruses and cancer. <i>Cancer Biology and Medicine</i> , 2016, 13, 483.	1.4	78
77	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. <i>Translational Lung Cancer Research</i> , 2016, 5, 532-537.	1.3	5
78	Annual or biennial lung cancer CT screening?. <i>Journal of Thoracic Disease</i> , 2016, 8, 2424-2426.	0.6	3
79	Unraveling the genomic complexity of small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 363-366.	1.3	27
80	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. <i>Translational Lung Cancer Research</i> , 2016, 5, 525-531.	1.3	22
81	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6361-6376.	1.0	21
82	Liquid Biopsy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2016, 3, 69.	1.2	48
83	RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1623-1625.	5.1	7
84	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. <i>Pulmonary Therapy</i> , 2016, 2, 1-18.	1.1	2
85	Trends in immunotherapy for brain metastases. <i>Lancet Oncology</i> , The, 2016, 17, 859-860.	5.1	8
86	Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 401-402.	12.5	35
87	Large-scale screening for somatic mutations in lung cancer. <i>Lancet</i> , The, 2016, 387, 1354-1356.	6.3	111
88	SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2396-2404.	3.2	103
89	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
90	Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , 2016, 10, 417-430.	0.6	21

#	ARTICLE	IF	CITATIONS
91	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. <i>Oncotarget</i> , 2016, 7, 56619-56627.	0.8	16
92	Immune checkpoint blockade (ICB) for first line treatment in non-small cell lung cancer (NSCLC). <i>Translational Cancer Research</i> , 2016, 5, S408-S410.	0.4	3
93	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016, 5, 2-15.	1.3	52
94	Targeted drugs in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 51-70.	1.3	28
95	Preface on small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 1.	1.3	41
96	Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. <i>EBioMedicine</i> , 2015, 2, 782-783.	2.7	0
97	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. <i>Melanoma Research</i> , 2015, 25, 486-495.	0.6	73
98	Evaluation of Biomarkers for HER3-targeted Therapies in Cancer. <i>EBioMedicine</i> , 2015, 2, 192-193.	2.7	3
99	Optimizing lung cancer treatment approaches. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 75-76.	12.5	59
100	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256.	9.4	434
101	Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	3.4	224
102	Relationship between gene mutation and lung cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 243-248.	2.7	17
103	Pharmacogenomics in the treatment of lung cancer: an update. <i>Pharmacogenomics</i> , 2015, 16, 1751-1760.	0.6	6
104	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	15.2	245
105	Platelets and their role in cancer evolution and immune system. <i>Translational Lung Cancer Research</i> , 2015, 4, 713-20.	1.3	15
106	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
107	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
108	Real-time liquid biopsies become a reality in cancer treatment. <i>Annals of Translational Medicine</i> , 2015, 3, 36.	0.7	85

#	ARTICLE	IF	CITATIONS
109	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	1.4	35
110	Tumor immune microenvironment characterization and response to anti-PD-1 therapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 74-8.	1.4	60
111	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	1.4	28
112	Advances in immunotherapy for treatment of lung cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 209-22.	1.4	50
113	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 704-12.	1.3	8
114	Immunotherapy meets targeted therapy: will this team end the war against cancer?. <i>Translational Lung Cancer Research</i> , 2015, 4, 752-5.	1.3	1
115	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 807-815.	1.1	17
116	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. <i>Lancet Respiratory Medicine</i> , 2014, 2, 966-968.	5.2	14
117	The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. <i>Clinical Cancer Research</i> , 2014, 20, 2001-2010.	3.2	215
118	Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors. <i>Current Pharmaceutical Design</i> , 2014, 20, 3883-3893.	0.9	6
119	Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Translational Lung Cancer Research</i> , 2014, 3, 70-4.	1.3	51
120	ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. <i>Translational Lung Cancer Research</i> , 2014, 3, 122-30.	1.3	25
121	Predicting resistance by selection of signaling pathways. <i>Translational Lung Cancer Research</i> , 2014, 3, 107-15.	1.3	21
122	A critical question for cancer therapy: what new targets exist?. <i>Translational Lung Cancer Research</i> , 2014, 3, 384-8.	1.3	3
123	Genetics and biomarkers in personalisation of lung cancer treatment. <i>Lancet</i> , 2013, 382, 720-731.	6.3	266
124	KRAS Mutations in Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 205-214.	1.1	182
125	Maintenance therapy and precision medicine in NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 549-550.	12.5	46
126	Small-cell lung cancer: where are we now and what can we expect for the future?. <i>Future Oncology</i> , 2013, 9, 1065-1068.	1.1	1

#	ARTICLE	IF	CITATIONS
127	BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 295-300.	0.5	17
128	Optimal Detection of ALK Rearranged Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2013, 8, 255-256.	0.5	19
129	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP2A, TOP2B and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. <i>PLoS ONE</i> , 2013, 8, e74611.	1.1	31
130	Adaptive resistance to targeted therapies in cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 152-9.	1.3	36
131	The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2013, 2, 172-9.	1.3	46
132	Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 180-8.	1.3	3
133	Comprehensive molecular screening: from the RT-PCR to the RNA-seq. <i>Translational Lung Cancer Research</i> , 2013, 2, 87-91.	1.3	48
134	CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. <i>Translational Lung Cancer Research</i> , 2013, 2, 65-71.	1.3	16
135	Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2013, 2, 208-21.	1.3	18
136	ALK and ROS1 as a joint target for the treatment of lung cancer: a review. <i>Translational Lung Cancer Research</i> , 2013, 2, 72-86.	1.3	29
137	Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors. <i>Annals of Palliative Medicine</i> , 2013, 2, 114-7.	0.5	6
138	Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study. <i>Translational Lung Cancer Research</i> , 2013, 2, 58-61.	1.3	1
139	Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non-Small-Cell Lung Cancer Pretreated With Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study. <i>Clinical Lung Cancer</i> , 2011, 12, 100-105.	1.1	6